Skip to main content
. 2013 Aug 27;5(8):417–424. doi: 10.4254/wjh.v5.i8.417

Figure 11.

Figure 11

Hepatocellular carcinomas after sorafenib. A: Pretreatment arterial phase computed tomography (CT) shows a large hypervascular hepatocellular carcinoma (HCC) (arrow) in right hepatic lobe; B: Arterial phase CT obtained at the same level of A, 9 mo after the start of sorafenib, shows increase in size of HCC (arrow); C: Pretreatment arterial phase CT image shows a second, small hypervascular HCC (arrow) arising within a larger hypoattenuating dysplastic nodule in left hepatic lobe; D: Arterial phase CT obtained at the same level of C, 9 mo after the start of sorafenib, shows disappearance of HCC enhancement (arrow). This case shows that different HCC response to sorafenib may occur in the same patient.